Global Orphan Diseases Partnering Deal Trends, Players and Financials Report 2010-2017

Global Orphan Diseases Partnering 2010 to 2017 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.The initial chapters of this report provide an...

Global Orphan Diseases Partnering 2010 to 2017 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.

The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target.

Report scope:

In Global Orphan Diseases Partnering 2010 to 2017, available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Orphan Diseases dealmaking

Chapter 3 -Financial deal terms for Orphan Diseases partnering

Chapter 4 - Leading Orphan Diseases deals and dealmakers

Chapter 5 - Orphan Diseases contract document directory

Chapter 6 - Orphan Diseases dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/d2qn4v/global_orphan

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716